Universal Imaging for GCA in #PMR? Not So Fast https://t.co/p581kXSzAb https://t.co/UIQjCxAzym

Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/3hb5Z7L9uw https://t.co/4gvSurl1nM

2023 EULAR Lupus Management Recommendations EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations. https://t.co/9PKvsEUTM3 https://t.co/gElp6tyEQZ

JAKne? Systematic review &meta-analysis (25 studies, 10 839 pts), JAK inhibitor use was associated with an elevated odds of acne (OR 3-5 for UPA, TOFA, BARI, Deucra; but higher for abrocitinib (OR 13.5). Seen in Derm pts but hardly at all in Rheum pts https://t.co/0XYeLLPDlK https://t.co/xN0PR1gj08

Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/KtdQgTvw4o https://t.co/R70sj3oYPH

Genetic links for Raynauds Phen (RP): Large GWAS study of 5147 RP cases in the UK Biobank cohort shows 2 robust and strong (p < 4.8 × 10−13) novel loci A) ADRA2A (rs7090046, OR per allele: 1.26) & B) IRX1 (rs12653958, OR: 1.17) as candidate causal genes https://t.co/Jho4CKmITU https://t.co/Gstxdejpc0

RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD

When #PMR Strikes Young, It Hits Hard In this blogpost I want to talk about “young PMR”: when people develop PMR in what should be the prime of their lives. By this I mean people under 65, and even people under 50. https://t.co/jHlppnddFf https://t.co/aB81hrYyHX

Controversies in #PMR A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting. Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese. Moderated by Dr. David Liew. https://t.co/QLkypnPA2G https://t.co/y5EiLkB2yq

#PMR Mythbusters: PMR is Only Proximal https://t.co/tRed7Zsaxi https://t.co/PWP5boH6NA

ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis The ACR has published its updated recommendations for prevention and treatment of GIOP for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily. https://t.co/oKVovOafl7 https://t.co/irxsAxMwKA

#PMR and Telemedicine: do we really need an office visit? Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis? https://t.co/JTAYstzDk8 https://t.co/NNvYfdkm2K